Gujarat Kidney and Super Speciality Limited has disclosed that its promoters and promoter group did not create any encumbrance on their shares during the financial year 2025-2026. The declaration was submitted to the stock exchanges in compliance with regulatory requirements regarding substantial acquisition of shares and takeovers.

Pragnesh Bharpoda, a promoter of the company, confirmed on behalf of all promoters and persons acting in concert that no shares were encumbered directly or indirectly during the specified period. The disclosure was made to BSE Limited and National Stock Exchange of India Limited on April 7, 2026.

The filing was made pursuant to Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any encumbrance created on their holdings to ensure transparency for shareholders.

Gujarat Kidney and Super Speciality Limited (GKSL) has announced the procurement of 100 AI-enabled haemodialysis machines, marking a significant expansion of its technology-driven renal care capabilities across Gujarat. The company has entered into an arrangement for the procurement of these units, with Phase-1 deployment of 8 machines scheduled at its Gujarat Multi Speciality Hospital, Godhra facility within the next 10 days. All required technical inspections have been completed successfully ahead of the rollout. The announcement was made under Regulation 30 and communicated to BSE Limited and the National Stock Exchange of India Limited, signed by Managing Director Dr. Praggnesh Bharpoda on 14 May 2026.

Phase-1 Deployment at Godhra Facility

The first phase of the rollout focuses on the Godhra facility, where 8 AI-based haemodialysis machines are to be installed and commissioned. Key highlights of the Phase-1 deployment are outlined below:

Trained clinical and technical teams are reported to be in place to operate the new platform from day one. The expanded session capacity is intended to enable GKSL to serve more patients from Godhra and adjoining districts, reducing the need for travel to tertiary care centres.

Why AI-Enabled Haemodialysis Matters

Unlike conventional dialysis equipment, AI-based haemodialysis machines continuously analyse intra-session data — including fluid balance, blood pressure trends, ultrafiltration response, and other clinical parameters — to support safer and more personalised treatment for each patient. The key clinical and operational benefits highlighted by the company include:

• Real-time decision support for nephrologists and dialysis technicians during each session
• Early detection of intradialytic complications such as hypotension and cramping
• Personalised treatment parameters adapted to each patient's clinical profile
• Improved consistency, traceability, and audit-readiness of every dialysis session

Network-Wide Rollout Plan

The remaining machines from the 100-unit procurement will be progressively deployed across GKSL's network of dialysis centres in a phased manner, in line with site readiness and clinical demand. The investment is intended to substantially scale up access to high-quality, technology-enabled renal care across Gujarat. The expansion aligns with the company's stated strategic objective of scaling up dialysis capacity and strengthening technology-enabled patient care across its network of healthcare facilities in the state.